Mechanisms for oxidative stress in diabetic cardiovascular disease

Antioxidants and Redox Signaling

Volumn 9, Issue 7, 2007, Pages 955-969

  Pennathur, Subramaniam ^a,c   Heinecke, Jay W ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL DERIVATIVE; GLUCOSE; LIPID; OXIDIZING AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIABETES MELLITUS; GAS CHROMATOGRAPHY; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN RESISTANCE; LIPID OXIDATION; MASS SPECTROMETRY; METABOLIC SYNDROME X; MICROENVIRONMENT; NONHUMAN; OBESITY; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; VASCULAR TISSUE;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

ANIMALIA;

EID: 34250325126     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2007.1595     Document Type: Review

References (153)

1. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, Minnemann T, Shulman GI, and Kahn BB. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729-733, 2001.
2. Abu-Soud HM and Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 275: 37524-37532, 2000.
3. American Diabetes Association. Diabetes Statistics. http:// wwwdiabetesorg/diabetes-statisticsjsp, 2007. (Accessed January 28, 2007.)
4. Ames BN, Shigenaga MK, and Hagen TM. Oxidants, antioxidants and the degenerative diseases of aging. Proc Natl Acad Sci USA 90: 7915-7922, 1993.
5. Baynes JW and Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28: 1708-1716, 2000.
6. Baynes JW and Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9, 1999.
7. Beckman JS, Chen J, Ischiropoulos H, and Crow JP. Oxidative chemistry of peroxynitrite. Methods Enzymol 233: 229-240, 1994.
8. Bergt C, Pennathur S, Fu X, Byun J, O'Brien K, McDonald TO, Singh P, Anantharamaiah GM, Chait A, Brunzell J, Geary RL, Oram JF, and Heinecke JW. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA 101: 13032-13037, 2004.
9. Bhattacharjee S, Pennathur S, Byun J, Crowley J, Mueller D, Gischler J, Hotchkiss RS, and Heinecke JW. NADPH oxidase of neutrophils elevates o,o′-dityrosine cross-links in proteins and urine during inflammation. Arch Biochem Biophys 395: 69-77, 2001.
10. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, and Green MS. Secondary prevention with antioxidants of cardiovascular disease in end stage renal disease (SPACE): randomised placebo controlled trial. Lancet 356: 1213-1218, 2000.
11. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, and Holman RR. Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551-1562, 2006.
12. Brennan ML and Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 14: 353-359, 2003.
13. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, and Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349: 1595-1604, 2003.
14. Brown MS and Goldstein JL. Koch's postulates for cholesterol. Cell 71: 187-188, 1992.
15. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234, 1995.
16. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
17. Brownlee M, Vlassara H, Kooney A, Ulrich P, and Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986.
18. Bucala R, Makita Z, Koschinsky T, Cerami A, and Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90: 6434-6438, 1993.
19. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, and Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91: 9441-9445, 1994.
20. Bucala R and Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 26: 875-888, 1995.
21. Butler R, Morris AD, Belch JJ, Hill A, and Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 35: 746-751, 2000.
22. Carew TE, Schwenke DC, and Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84: 7725-7729, 1987.
23. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, and Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8: 691-728, 2006.
24. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2003. US Department of Health and Human Services, Centers for Disease Control and Prevention. Atlanta GA, 2004.
25. Chalupsky K and Cai H. Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 102: 9056-9061, 2005.
26. Collins R, Armitage J, Parish S, Sleigh P, and Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016, 2003.
27. Daugherty A, Dunn JL, Rateri DL, and Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444, 1994.
28. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, and Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229, 1999.
29. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
30. DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342: 381-389, 2000.
31. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, and Baynes JW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61: 939-950, 2002.
32. DREAM Trial Investigators. The Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Lancet 368: 1096-1105, 2006.
33. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, and Brownlee M. Hyperglycemi-induced mitochondrial superoxide overproduction activates hexosamine pathway and induces plasminogen-activator inhibitor-1 expression by increasing Sp-1 glycosylation. Proc Natl Acad Sci USA 97: 12222-12226, 2000.
34. Dyer DG, Blackledge JA, Thorpe SR, and Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266: 11654-11660, 1991.
35. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, and Baynes JW. Accumulation of maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91: 2463-2469, 1993.
36. Edelstein D and Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35: 96-97, 1992.
37. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, and van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391: 393-397, 1998.
38. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 111: 431-433, 2003.
39. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, and Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986, 1996.
40. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, Belaaouaj A, and Heinecke JW. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest 109: 1311-1319, 2002.
41. Glass CK and Witztum JL. Atherosclerosis. the road ahead. Cell 104: 503-516, 2001.
42. Goldstein JL, Ho YK, Basu SK, and Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 76: 333-337, 1979.
43. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, and Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2552-2563, 2006.
44. Haberland ME, Fong D, and Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 241: 215-218, 1988.
45. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 342: 1040-1042, 2000.
46. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
47. Hammes HP, Brownlee M, Edelstein D, Saleck M, Martin S, and Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 37: 32-35, 1994.
48. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, and Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9: 294-299, 2003.
49. Hammes HP, Martin S, Federlin K, Geisen K, and Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 88: 11555-11558, 1991.
50. Hazell LJ and Stocker R. Alpha-tocopherol does not inhibit hypochlorite-induced oxidation of apolipoprotein B-100 of low-density lipoprotein. FEBS Lett 414: 541-544, 1997.
51. Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol 24: 1143-1146, 2004.
52. Hazen SL and Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 99: 2075-2081, 1997.
53. Heinecke JW. Clinical trials of vitamin E in coronary artery disease: is it time to reconsider the low-density lipoprotein oxidation hypothesis? Curr Atheroscler Rep 5: 83-87, 2003.
54. Heinecke JW. Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler Thromb Vasc Biol 21: 1261-1264, 2001.
55. Heinecke JW. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 13: 1113-1120, 1999.
56. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 91: 12A-16A, 2003.
57. Heinecke JW. Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radic Biol Med 32: 1090-1101, 2002.
58. Heinecke JW. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors 6: 145-155, 1997.
59. Heinecke JW, Rosen H, and Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 74: 1890-1894, 1984.
60. HOPE Study Group. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253-259, 2000.
61. Houstis N, Rosen ED, and Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440: 944-948, 2006.
62. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, and Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 161: 1717-1723, 2001.
63. Huggins TG, Staton MW, Dyer DG, Detorie NJ, Walla MD, Baynes JW, and Thorpe SR. o-Tyrosine and dityrosine concentrations in oxidized proteins and lens proteins with age. Ann NY Acad Sci 663: 436-437, 1992.
64. Huggins TG, Wells-Knecht MC, Detorie NA, Baynes JW, and Thorpe SR. Formation of o-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J Biol Chem 268: 12341-12347, 1993.
65. Hunt JV, Dean RT, and Wolff SP. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem J 256: 205-212, 1988.
66. Hunt JV, Smith CC, and Wolf SP. Oxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39: 1420-1424, 1990.
67. Ido Y, Kilo C, and Williamson JR. Cytosolic NADH/NAD supply, free radicals and vascular dysfunction in early diabetes mellitus. Diabetologia 40: S115-S117, 1997.
68. Ihm S, Hyung J, Park S, and Ihm J. Effect of aminoguanidine on lipid-peroxidation in streptozotocin-induced diabetic rats. Metabolism 48: 1141-1145, 1999.
69. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, and Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-1945, 2000.
70. Ishii H, Daisuke K, and King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 76: 21-31, 1998.
71. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, and King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731, 1996.
72. Jay D, Hitomi H, and Griendling KK. Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40: 183-192, 2006.
73. Kaur H and Halliwell B. Detection of hydroxyl radicals by aromatic hydroxylation. Meth Enzymol 233: 67-82, 1994.
74. Kawamura M, Heinecke JW, and Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 94: 771-778, 1994.
75. King GL, Ishii H, and Koya D. Diabetic vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int Suppl 60: S77-85, 1997.
76. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, and Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84: 5928-5931, 1987.
77. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 93: 480-489, 1980.
78. Klebanoff SJ and Clark RA. The Neutrophil: Function and Clinical Disorders. Amsterdam: North Holland Biochemical Press, 1978, p. 447-451.
79. Klein R, Klien BE, and Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: a review. Diabetes Metab Rev 5: 559-570, 1989.
80. Lamharzi N, Renard CB, Kramer F, Pennathur S, Heinecke JW, Chait A, and Bornfeldt KE. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 53: 3217-3225, 2004.
81. Leeuwenburgh C, Hansen P, Shaish A, Holloszy JO, and Heinecke JW. Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. Am J Physiol 274: R453-461, 1998.
82. Leeuwenburgh C, Hansen PA, Holloszy JO, and Heinecke JW. Oxidized amino acids in the urine of aging rats: potential markers for assessing oxidative stress in vivo. Am J Physiol 276: R128-135, 1999.
83. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh-ishi S, Steinbrecher UP, and Heinecke JW. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272: 1433-1436, 1997.
84. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, and Heinecke JW. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 272: 3520-3526, 1997.
85. Lorenzi M and Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 44: 791-804, 2001.
86. Maitra I, Serbinova E, Trischler H, and Packer L. a-Lipoic acid prevents buthionine sulfoximine-induced cataract formation in newborn rats. Free Radical Biol Med 18: 823-829, 1995.
87. Mashima R, Witting PK, and Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 12: 411-418, 2001.
88. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB, Sr., Perez A, Provost JC, and Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296: 2572-2581, 2006.
89. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, and Lyons TJ. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470-2478, 1993.
90. Meagher EA, Barry OP, Lawson JA, Rokach J, and FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 285: 1178-1182, 2001.
91. Mezzetti A, Cipollone F, and Cuccurullo F. Oxidative stress and cardiovascular complications of diabetes: isoprostanes as new markers on an old paradigm. Cardiovas Res 47: 475-488, 2000.
92. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, and Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 54: 1290-1295, 1998.
93. Miyata T, Ueda Y, Yoshido A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, and van Ypersele de Strihou C. Clearance of pentosidine, an advanced glycation end-product, by different modalities of renal replacement therapy. Kidney Int 51: 880-887, 1997.
94. Miyata T, van Ypersele de Strihou C, Kurokawa K, and Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399, 1999.
95. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 107: 799-801, 2001.
96. Morel DW, DiCorleto PE, and Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 4: 357-364, 1984.
97. Nagamatsu M, Nickander KK, Schmelzer JD, Ray A, Wittrock DA, Tritschler H, and Low PA. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18: 1160-1167, 1995.
98. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 352: 832-833, 1998.
99. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, and Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653, 2005.
100. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, and Genuth S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348: 2294-2303, 2003.
101. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, and Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790, 2000.
102. Oak JH and Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 56: 118-126, 2007.
103. Obrosova IG, Fathallah L, and Greene DA. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur J Pharmacol 398: 139-146, 2000.
104. Onorato JM, Jenkins AJ, Thorpe SR, and Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 275: 21177-21184, 2000.
105. Packer L, Witt EH, and Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biol Med 19: 227-250, 1995.
106. Parthasarathy S, Young SG, Witztum JL, Pittman RC, and Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77: 641-644, 1986.
107. Pennathur S, Bergt C, Shao B, Byun J, Kassim SY, Singh P, Green PS, McDonald TO, Brunzell J, Chait A, Oram JF, O'Brien K, Geary RL, and Heinecke JW. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 279: 42977-42983, 2004.
108. Pennathur S and Heinecke JW. Mechanisms of oxidative stress in diabetes: implications for the pathogenesis of vascular disease and antioxidant therapy. Front Biosci 9: 565-574, 2004.
109. Pennathur S, Ido Y, Heller JI, Byun J, Danda R, Pergola P, Williamson JR, and Heinecke JW. Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: a potential pathway for oxidative damage of retinal proteins in diabetes. J Biol Chem 280: 22706-22714, 2005.
110. Pennathur S, Jackson-Lewis V, Przedborski S, and Heinecke JW. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 274: 34621-34628, 1999.
111. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, and Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107: 853-860, 2001.
112. Pfeiffer A and Schatz H. Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes 103: 7-14, 1995.
113. Pilz S, Scharnagl H, Tiran B, Seelhorst U, Wellnitz B, Boehm BO, Schaefer JR, and Marz W. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J Clin Endocrinol Metab 91: 2542-2547, 2006.
114. Requena JR, Ahmed MU, Fountain CW, Degenhardt TP, Reddy S, Perez C, Lyons TJ, Jenkins AJ, Baynes JW, and Thorpe SR. Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivo. J Biol Chem 272: 17473-17479, 1997.
115. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, Baynes JW, and Thorpe SR. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochem J 322 ( Pt 1): 317-325, 1997.
116. Requena JR, Fu MX, Ahmed MU, Jenkins AJ, Lyons TJ, and Thorpe SR. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Nephrol Dial Transplant 11 suppl 5: 48-53, 1996.
117. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 340: 115-126, 1999.
118. Salvemini D, Wang Z, Zwier JL, Samouilov A, Macarthur H, Misko T, Currie MG, Cuzzocrea S, Sikorski JA, and Riley DP. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 286: 304-306, 1999.
119. Savenkova ML, Mueller DM, and Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 269: 20394-20400, 1994.
120. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, and Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 45 suppl 3: S77-80, 1996.
121. Sell DR, Lapolla A, Odetti P, Fogarty J, and Monnier VM. Pentosidine formation in skin correlates with the severity of complications in individuals with long -standing IDDM. Diabetes 41: 1286-1292, 1992.
122. Semenkovich CF and Heinecke JW. The mystery of diabetes and atherosclerosis: time for a new plot. Diabetes 46: 327-334, 1997.
123. Shao B, Oda MN, Oram JF, and Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 21: 322-328, 2006.
124. Sharma K and Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem Nephrol 17: 80-92, 1997.
125. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, and Hazen SL. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289: 1675-1680, 2003.
126. Shishehbor MH, Brennan ML, Aviles RJ, Fu X, Penn MS, Sprecher DL, and Hazen SL. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 108: 426-431, 2003.
127. Shishehbor MH and Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep 6: 243-250, 2004.
128. Sonta T, Inoguchi T, Tsubouchi H, Sekiguchi N, Kobayashi K, Matsumoto S, Utsumi H, and Nawata H. Evidence for contribution of vascular NAD(P)H oxidase to increased oxidative stress in animal models of diabetes and obesity. Free Radic Biol Med 37: 115-123, 2004.
129. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 8: 1211-1217, 2002.
130. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81: 3883-3887, 1984.
131. Stern DM, Yan SD, Yan SF, and Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1: 1-15, 2002.
132. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, and Thorpe SR. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832, 2002.
133. UKPDS Research Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [see comments] [published erratum appears in Lancet 1998 Nov 7;352:1557]. Lancet 352: 854-865, 1998.
134. UKPDS Research Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [see comments]. Lancet 352: 837-853, 1998.
135. Van Gaal LF, Mertens IL, and De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880, 2006.
136. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, and Pritchard KA, Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 95: 9220-9225, 1998.
137. Voziyan PA, Metz TO, Baynes JW, and Hudson BG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277: 3397-3403, 2002.
138. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, and Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-694, 2001.
139. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL, and Ferrante AW, Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115-124, 2006.
140. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, and Ferrante AW, Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
141. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, and Baynes JW. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 100: 839-846, 1997.
142. Wild S, Roglic G, Green A, Sicree R, and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
143. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, and Tilton RG. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813, 1993.
144. Witztum JL and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88: 1785-1792, 1991.
145. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, and Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362, 2005.
146. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, and Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arlerioscler Thromb 14: 32-40, 1994.
147. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, and Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095, 1989.
148. Yusuf S, Dagenais G, Pogue J, Bosch J, and Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154-160, 2000.
149. Zhang SX, Sima J, Shao C, Fant J, Chen Y, Rohrer B, Gao G, and Ma JX. Plasminogen kringle 5 reduces vascular leakage in the retina in rat models of oxygen-induced retinopathy and diabetes. Diabetologia 47: 124-131, 2004.
150. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, and Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114: 529-541, 2004.
151. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K, Kerum G, and Malessa R. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22: 1296-1301, 1999.
152. Ziegler D, Reljanovic M, Mehnert H, and Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 107: 421-430, 1999.
153. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, and Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathic. Diabetes Care 20: 369-373, 1997.